malondialdehyde has been researched along with penconazole in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boudawara, T; Chaâbane, M; Chelly, S; Ellouze Chaabouni, S; Elwej, A; Ghorbel, I; Mnif, H; Soudani, N; Zeghal, N | 1 |
| Al Dulmani, SA; Al-Zahrani, FAM; Galal, MK; Hassanen, EI; Hussien, AM; Ibrahim, MA; Kamel, S; Morgan, AM; Ogaly, HA; Rashad, MM | 1 |
2 other study(ies) available for malondialdehyde and penconazole
| Article | Year |
|---|---|
Penconazole alters redox status, cholinergic function and lung's histoarchitecture of adult rats: Reversal effect of vitamin E.
Topics: Acetylcholinesterase; Animals; Antioxidants; Body Weight; Cholinergic Agents; Hydrogen Peroxide; Lipid Peroxidation; Lung; Lung Injury; Male; Malondialdehyde; Organ Size; Oxidation-Reduction; Rats, Wistar; Triazoles; Vitamin E | 2018 |
The ameliorative effect of N-acetylcysteine against penconazole induced neurodegenerative and neuroinflammatory disorders in rats.
Topics: Acetylcysteine; Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Brain; Caspase 3; Elevated Plus Maze Test; Male; Malondialdehyde; Neurodegenerative Diseases; Neuroinflammatory Diseases; Neuroprotective Agents; Oxidative Stress; Rats; Rats, Sprague-Dawley; Signal Transduction; Treatment Outcome; Triazoles | 2021 |